Browse All

Current Filters

CLEAR FILTER x

TITLE

Efficacy and Safety Results of INFRONT-3: A Phase 3 Randomized, Double-Blind, Placebo Controlled Study Evaluating Latozinemab (AL001) in FTD-GRN

Author:MAYORGA, ARTHUR   Boeve, Bradley   Le Ber, Isabelle   Borroni, Barbara   Mummery, Catherine   Rohrer, Jonathan   Zamboni, Giovanna   Onur, Oezguer   Rowe, James   Boxer, Adam   Schwabe, Tina   Kahn, Olga   Huang, Julie   Gupta, Ruchi   Zhong, Jinglin   Li, Caiyan   Guizzetti, Leonardo   Carter, Lawrence   Nguyen, Tuan   Simmons, Adam   Chow, Tiffany   Budda, Balasubrahmanyam   Park, Lovingly   Jackson, Sam   Paul, Robert   Romano, Gary   Kenkare-Mitra, Sara   Rosenthal, Arnon   Salvadore, Giacomo   

Session Name:LS2: Late-breaking Science 2  

Topic:Aging, Dementia, and Behavioral Neurology  

Program Number:Aging, Dementia, and Behavioral Neurology  

Author Institution:Alector, Inc., DOYLESTOWN, PA  Mayo Clinic, Rochester, MN  AP HP, Paris, France  University of Brescia, Italy  University College London Hospitals, London NW1 2BU, United Kingdom  Dementia Research Centre, London, United Kingdom  University of Modena and Reggio Emilia, Reggio Emilia, Italy  University Hospital Cologne, Germany  University of Cambridge, Cambridge, United Kingdom  University of California, San Francisco, San Francisco, CA  Alector, Inc., South San Francisco, CA  Alector, Inc., San Francisco, CA